SG Americas Securities LLC Sells 5,846 Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB)

SG Americas Securities LLC reduced its stake in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB – Get Rating) by 55.2% in the third quarter, HoldingsChannel.com reports. The firm owned 4,740 shares of the medical instruments supplier’s stock after selling 5,846 shares during the period. SG Americas Securities LLC’s holdings in Mesa Laboratories were worth $668,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. State of New Jersey Common Pension Fund D boosted its stake in Mesa Laboratories by 30.0% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 13,929 shares of the medical instruments supplier’s stock worth $1,962,000 after purchasing an additional 3,216 shares during the period. Raymond James & Associates grew its holdings in Mesa Laboratories by 3.8% in the 3rd quarter. Raymond James & Associates now owns 46,438 shares of the medical instruments supplier’s stock worth $6,540,000 after acquiring an additional 1,719 shares during the last quarter. Louisiana State Employees Retirement System bought a new stake in shares of Mesa Laboratories in the 3rd quarter worth approximately $338,000. Cambridge Investment Research Advisors Inc. boosted its stake in shares of Mesa Laboratories by 5.8% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 5,224 shares of the medical instruments supplier’s stock valued at $736,000 after purchasing an additional 285 shares in the last quarter. Finally, Mackenzie Financial Corp raised its position in shares of Mesa Laboratories by 20.3% in the 3rd quarter. Mackenzie Financial Corp now owns 1,437 shares of the medical instruments supplier’s stock worth $202,000 after acquiring an additional 242 shares in the last quarter. 93.00% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

MLAB has been the subject of a number of analyst reports. Evercore ISI raised their target price on shares of Mesa Laboratories to $166.00 in a research note on Tuesday, November 15th. StockNews.com downgraded shares of Mesa Laboratories from a “hold” rating to a “sell” rating in a research report on Saturday.

Insider Buying and Selling

In other Mesa Laboratories news, Director Shannon Hall sold 230 shares of the firm’s stock in a transaction that occurred on Thursday, December 8th. The stock was sold at an average price of $174.97, for a total value of $40,243.10. Following the sale, the director now directly owns 957 shares of the company’s stock, valued at $167,446.29. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, Director Shannon Hall sold 230 shares of the firm’s stock in a transaction that occurred on Thursday, December 8th. The shares were sold at an average price of $174.97, for a total transaction of $40,243.10. Following the completion of the sale, the director now owns 957 shares in the company, valued at approximately $167,446.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director John Bradley Schmieder sold 2,500 shares of the business’s stock in a transaction on Friday, November 11th. The shares were sold at an average price of $175.45, for a total value of $438,625.00. Following the completion of the sale, the director now owns 68,976 shares in the company, valued at approximately $12,101,839.20. The disclosure for this sale can be found here. Insiders sold a total of 4,301 shares of company stock worth $779,416 in the last 90 days. 5.50% of the stock is owned by corporate insiders.

Mesa Laboratories Price Performance

NASDAQ:MLAB opened at $196.88 on Friday. Mesa Laboratories, Inc. has a 52 week low of $114.21 and a 52 week high of $302.80. The company has a quick ratio of 2.13, a current ratio of 2.80 and a debt-to-equity ratio of 0.53. The stock has a market cap of $1.05 billion, a PE ratio of -259.05 and a beta of 0.68. The business’s 50-day simple moving average is $175.46 and its two-hundred day simple moving average is $170.57.

Mesa Laboratories (NASDAQ:MLAB – Get Rating) last released its earnings results on Thursday, November 3rd. The medical instruments supplier reported $2.07 earnings per share for the quarter, beating the consensus estimate of $0.83 by $1.24. The firm had revenue of $58.75 million for the quarter, compared to the consensus estimate of $53.24 million. Mesa Laboratories had a positive return on equity of 6.71% and a negative net margin of 1.78%. As a group, analysts forecast that Mesa Laboratories, Inc. will post 6.52 EPS for the current fiscal year.

Mesa Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 15th. Investors of record on Tuesday, February 28th will be paid a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.33%. The ex-dividend date is Monday, February 27th. Mesa Laboratories’s dividend payout ratio (DPR) is -84.21%.

Mesa Laboratories Company Profile

(Get Rating)

Mesa Laboratories, Inc develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries.